JPMorgan Downgrades bluebird bio (BLUE) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. FND
9. DASH
10. GILD

Go back to JPMorgan Downgrades bluebird bio (BLUE) to Neutral

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

August 14, 2024 7:00 AM EDT

- 27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA); anticipate approximately 85 patient starts across the portfolio as LYFGENIA patient starts accelerate in the second half of 2024 -

- Second quarter 2024 net revenue of $16.1 million -

- Cash runway into Q2 2025 based on current operating plans and cash on hand -

- Management to host conference call today, August 14, 2024 at 8:00 am ET -

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today reported... More